Glioblastoma treatment: Bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 1, 2012, Pages 244-249

  Charest, Gabriel ^a   Sanche, Léon ^a   Fortin, David ^b   Mathieu, David ^b   Paquette, Benoit ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

F98 glioma; Fischer rats; Gamma radiation; Liposomes; Platinum compounds

Indexed keywords

ADVERSE EFFECT; ANTICANCER ACTIVITIES; CANCER CELLS; CARBOPLATIN; CIS-PLATIN; F98 GLIOMA; GLIOBLASTOMAS; INTRACAROTID; LIPOSOMAL FORMULATION; OVERALL SURVIVAL; OXALIPLATIN; RIGHT HEMISPHERES; SIDE EFFECT; TREATMENT EFFICIENCY; TUMOR RESPONSE; TUMOR UPTAKE;

GAMMA RAYS; LIPOSOMES; PLATINUM; RADIOTHERAPY; RATS; TOXICITY; TUMORS;

PLATINUM COMPOUNDS;

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; LIPOPLATIN; LIPOXAL; OXALIPLATIN; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG INTOXICATION; DRUG SPECIFICITY; DRUG TUMOR LEVEL; GLIOBLASTOMA; MULTIMODALITY CANCER THERAPY; NONHUMAN; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RAT; RIGHT HEMISPHERE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARBOPLATIN; CAROTID ARTERIES; CISPLATIN; COMBINED MODALITY THERAPY; GLIOBLASTOMA; INFUSIONS, INTRA-ARTERIAL; LIPOSOMES; ORGANOPLATINUM COMPOUNDS; RADIOSURGERY; RATS; RATS, INBRED F344;

EID: 84865686167     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.10.054     Document Type: Article

References (20)

1. K. Chaichana, S. Parker, A. Olivi, and A. Quinones-Hinojosa A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme J Neurosurg 112 2010 997 1004
2. S. Sathornsumetee, and J.N. Rich Designer therapies for glioblastoma multiforme Ann N Y Acad Sci 1142 2008 108 132
3. A. Chakravarti, and K. Palanichamy Overcoming therapeutic resistance in malignant gliomas: Current practices and future directions Cancer Treat Res 139 2008 173 189
4. US Department of Health & Human Services. US Food and Drug Administration. Orange book: Approved drug products with therapeutic equivalence evaluations. Active ingredient search results from "OB-Rx" table for query on "platin." Available from: URL: http://www.accessdata.fda.gov/ scripts/cder/ob/. Accessed Sept 2011.
5. L. Yang, E.B. Douple, J.A. O'Hara, R.A. Crabtree, and A. Eastman Enhanced radiation-induced cell killing by carboplatin in cells of repair-proficient and repair-deficient cell lines Radiat Res 144 1995 230 236
6. Y. Zheng, D.J. Hunting, P. Ayotte, and L. Sanche Role of secondary low-energy electrons in the concomitant chemoradiation therapy of cancer Phys Rev Lett 100 2008 198101
7. T. Boulikas Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin. Lipoplatin as a chemotherapy and antiangiogenesis drug Cancer Ther 5 2007 349 376
8. T. Boulikas, and M. Vougiouka Cisplatin and platinum drugs at the molecular level. (Review) Oncol Rep 10 2003 1663 1682
9. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review J Control Release 65 2000 271 284
10. T. Kaasgaard, and T.L. Andresen Liposomal cancer therapy: Exploiting tumor characteristics Expert Opin Drug Deliv 7 2010 225 243
11. N.D. Doolittle, M.E. Miner, and W.A. Hall Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors Cancer 88 2000 637 647
12. R.F. Barth Rat brain tumor models in experimental neuro-oncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas J Neurooncol 36 1998 91 102
13. D. Mathieu, and D. Fortin Chemotherapy and delivery in the treatment of primary brain tumors Curr Clin Pharmacol 2 2007 197 211
14. J. Blanchard, D. Mathieu, Y. Patenaude, and D. Fortin MR-pathological comparison in F98-Fischer glioma model using a human gantry Can J Neurol Sci 33 2006 86 91
15. D. Fortin, R. Adams, and A. Gallez A blood-brain barrier disruption model eliminating the hemodynamic effect of ketamine Can J Neurol Sci 31 2004 248 253
16. G. Charest, D. Mathieu, M. Lepage, D. Fortin, B. Paquette, and L. Sanche Polymer gel in rat skull to assess the accuracy of a new rat stereotactic device for use with the gamma knife Acta Neurochir (Wien) 151 2009 677 683
17. G. Charest, B. Paquette, D. Fortin, D. Mathieu, and L. Sanche Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation J Neurooncol 97 2010 187 193
18. T. Boulikas, G.P. Stathopoulos, N. Volakakis, and M. Vougiouka Systemic Lipoplatin infusion results in preferential tumor uptake in human studies Anticancer Res 25 2005 3031 3039
19. P. Soulie, E. Raymond, S. Brienza, and E. Cvitkovic Oxaliplatin: The first DACH platinum in clinical practice Bull Cancer 84 1997 665 673
20. S.B. Park, C.S. Lin, A.V. Krishnan, D. Goldstein, M.L. Friedlander, and M.C. Kiernan Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy Brain 132 Pt. 10 2009 2712 2723